BLOOD NO CONTENT AS A MARKER OF MALIGNANT THYROID TUMOUR PATHOLOGY
Keywords:thyreotoxicosis, tumour, carcinoma, NO
The identification of early diagnostic markers of tumour pathology of the thyroid gland plays an important role. Our study aimed to determine changes in NO metabolism in various benign and malignant thyroid pathologies. The content of NO in the blood serum of healthy individuals and patients (with thyrotoxicosis, benign thyroid tumour and thyroid cancer) was studied. In patients with thyrotoxicosis, the content of NO in the blood serum increases statistically significantly by 33%, and in benign tumour pathology - by 22% compared with control indicators; In patients with thyroid cancer, the content of NO in the blood serum did not statistically significantly different from the level of control parameters.The present study has the potential to present elevated levels of NO in the blood of patients, compared with controls, as a marker to rule out thyroid cancer. Further clinical studies are needed to obtain comprehensive results and elucidate the relationship between NO metabolism and thyroid pathologies.
World Health Organization. www.who.int
National cancer institute seer.cancer.gov
National Comprehensive Cancer Network. www.nccn.org
www. cancer research uk.org
Quesada A, Sainz J, Wangensteen R, Rodriguez-Gomez I, Vargas F, Osuna A. Nitric oxide synthase activity in hyperthyroid and hypothyroid rats. Eur J Endocrinol 2002;147(1):117-22.
Larsen PR, Davis TF, Hay ID. The thyroid gland. In Williams Textbook of Endocrinology, edn 6, pp 389-515. Eds JD Wilson, DW Foster, HK Kronenberg & PR Larsen. London: WB Saunders & Co., 1998.
Klein I. Thyroid hormone and the cardiovascular system. Am J Med 1990;88(6):631-7.
Gardiner SM, Compton AM, Bennett T, Palmer RMJ, Moncada S. Control of regional blood flow by endothelium-derived nitric oxide. Hypertension 1990;15(5):486-92.
Romero JC, Lahera V, Salom MG, Biondi ML. Role of the endothelium-dependent relaxing factor nitric oxide on renal function. Journal of the American Society of Nephrology 1992;2(9):1371-87.
Durante W, Johnson FK, Johnson RA. Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol 2007;34(9):906-11.
Uslu S, Ozcelik E, Kebapci N, Temel HE, Demirci F, Ergun B, Demirustu C. Effects of serum uric acid levels on the arginase pathway in women with metabolic syndrome. Ir J Med Sci 2016;185(1):259-63.
Kiss A, Tratsiakovich Y, Gonon AT et al. The role of arginase and rho kinase in cardioprotection from remote ischemic perconditioning in non-diabetic and diabetic rat in vivo. PLoS One. 2014; 20: 9(8): e104731.
Huseyin Vural, Mehmet Numan Tamer, Ralf Weiskirchen. Evaluation of Arginine-Nitric Oxide Pathway in Patients with Hyperthyroidism. Electronic Journal of General Medicine 2021, 18(2), em278 e-ISSN: 2516-3507
Miranda, K, Espey, M, Wink, D. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide: Biology and Chemistry. 2001; 5(1):62–71.
Seven R, Gelişgen R, Seven A, Erbil Y, Bozbora A, Burçak G. Influence of propylthiouracil treatment on oxidative stress and nitric oxide in Basedow disease patients. J Toxicol Environ Health A. 2001; 62(7):495-503.
Yalcın B, Duman C, Cekmen MB et al. The Effects of Propylthyouracil Therapy on the Nitric Oxide, Oxidants, Antioxidants in the Hyperthyroidic Patients. Turk Klinik Biyokimya Derg 2004; 2(1):1-7.
Hermenegildo C, Medina P, Peiró M, Segarra G, Vila JM, Ortega J, Lluch S. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in hyperthyroid patients. J Clin Endocrinol Metab. 2002; 7(12):5636-40.
Vargas F, Montes R, Sabio JM, García-Estañ J. Role of nitric oxide in the systemic circulation of conscious hyper- and hypothyroid rats. Gen Pharmacol. 1994; 25(5):887-91.
Vural H, Sirin B, Yilmaz N, Eren I, Delibas N. The role of arginine-nitric oxide pathway in patients with Alzheimer disease. Biol Trace Elem Res 2009; 129(1-3):58-64.